3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
3
Ovarian Neoplasms
2
Insulin-Like Growth Factor I, Resistance To
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Sarcoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
37
Carboplatin
26
Radiotherapy
23
Cisplatin
19
Paclitaxel
18
Erlotinib Hydrochloride
18
Docetaxel
15
Gemcitabine
14
Pemetrexed
13
Etoposide
12
osimertinib
11
Nivolumab
11
durvalumab
9
atezolizumab
9
Radiosurgery
8
Magnetic Resonance Spectroscopy
8
Cetuximab
7
Specimen Handling
6
Cyclophosphamide
6
130-nm albumin-bound paclitaxel
6
Taxes
5
Immunoglobulin G
5
Gefitinib
5
Biopsy
5
Bevacizumab
5
fludarabine
4
Radiation
4
Ipilimumab
4
Disulfides
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lung Neoplasms
×
ganitumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts